”
The 11th International BioCon China Expo 2024 was held in Beijing with the theme of "Adapting to Change and Striving for Change", and Fujifilm Owen Technology and Fujifilm and Light jointly created Fujifilm's Life Science booth, bringing cutting-edge products in industrial media and biopharmaceutical quality control respectively, actively responding to the diverse needs of the booming biopharmaceutical industry.
The International Biopharmaceutical Technology Exhibition is an important comprehensive professional platform for information exchange, technology sharing, product acquisition, and business docking in the domestic biopharmaceutical industry. The Fujifilm Life Science booth at BioCon China Expo 2024 attracted many professionals to stop and exchange consultations.
Among Fujifilm Owen Technologies' exhibits, the BalanCD HEK293 media platform consists of chemically defined, animal-derived BalanCD HEK293 medium and feeds to support the production of viral vectors, transient protein expression, and recombinant protein production for gene therapy. Formulated for industrial applications and a smooth transition from early stages to commercial biomanufacturing, the PRIME-XV media platform and a range of media optimization and product services support basic, translational, clinical, and commercial applications.
BalanCD HEK293 media platform
BalanCD CHO 细胞培养基平台
PRIME-XV 免疫/干细胞培养基
At the "Drug Full Life Cycle Development Forum", Fujifilm Owen Technology's product experts also explained the latest product perfusion medium in detail and communicated with the professional audience.
Among Fujifilm Wako's exhibits, the residual DNA extraction kit follows the sodium iodide method included in the Chinese Pharmacopoeia, which is compatible with qPCR downstream detection, simple operation, high safety and high recovery, and can be used with QCdetect™ series residual DNA detection kits for high sensitivity and high reproducibility residual DNA detection, and the endotoxin detector Toxinometer® ET-7000 complies with the "bacterial endotoxin detection method" of the United States/European/Japanese Pharmacopoeia. In addition to biopharmaceutical quality control products, CultureSure™ CEPT Cocktail, a small molecule mixture that supports the upstream and downstream production lines of iPSCs, is also exhibited to effectively improve the viability of hPSCs during cell passage and cryopreservation [1], and also promote the formation of embryoid bodies and organoids [1,2].
As the life sciences sector is undergoing a period of accelerated development, Fujifilm's life science business is committed to becoming a high-quality partner for biopharmaceutical companies by providing support from R&D to clinical trials with cell biology at its core. This year, on the occasion of its 90th anniversary, the Fujifilm Group announced its new mission, "More Smiles for the World," once again demonstrating its determination to contribute to a better future. Following in the footsteps of China's biopharmaceutical industry, Fujifilm will focus on unmet R&D and clinical needs to help biopharmaceutical companies enhance their competitiveness and achieve high-quality development of the industry.
Bibliography:
[1]. Chen, Y., Tristan, C. A., Chen, L., Jovanovic, V. M., Malley, C., Chu, P. H., ... & Singeç, I. (2021). A versatile polypharmacology platform promotes cytoprotection and viability of human pluripotent and differentiated cells. Nature methods, 18(5), 528-541.
[2]. Ryu, S., Weber, C., Chu, P. H., Tristan, C. A., Ernest, B., Jovanovic, V. M., ... & Singeç, I. (2022). Enhancing the fitness of embryoid bodies and organoids by chemical cytoprotection. BioRxiv, 2022-03.
Background:
Fujifilm Group: Comprised of Fujifilm Corporation and Fujifilm Business Innovation Corporation, 273 subsidiaries and more than 73,000 employees worldwide, with total sales of JPY 2,859 billion and operating profit of JPY 273.1 billion in FY2022. (As of March 2023)
Fujifilm (China) Investment Co., Ltd. was established on April 12, 2001 and is headquartered in Shanghai, with a registered capital of US$213.4 million, including digital cameras, imaging products, printing products, medical products, optoelectronic products, industrial materials, etc.